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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether
Esomeprazole (Nexium) is more safe and effective than Omeprazole (Prilosec) in
reducing Heartburn and in increasing the rate of esophageal healing in adults with
endoscopically diagnosed Erosive Esophagitis (EE)
STUDY DESIGN: A review of all English language randomized controlled double
blind comparative trials comparing the different forms of Proton Pump Inhibitors
from 2006-2009. The studies included participants 18-85 years old with GERD and
endoscopically diagnosed Erosive esophagitis.
DATA SOURCES: Randomized controlled Double Blind Comparative trials were
Found using PubMed and Cochrane Databases.
OUTCOME MEASURED: Outcomes measured were reduction in GERD symptoms and
healing of erosive esophagitis. Each Article measured symptoms based off of patient
daily journals and symptoms criteria scales. Measurement of esophageal healing was
done based off of the LA Classification scale. One article measured reduction of GERD
symptoms after 5 days of treatment and the other two measured reduction after 4 weeks
of treatment. Patients whos GERD symptoms were measured after 5 days of treatment
were assessed based on a 6 point symptom scale (0: none; 1: mild; 2: mild-moderate; 3:
moderate; 4: moderate-severe; 5: severe and/or intolerable).
RESULTS: All three RCTs in this review found that there were comparable effect on
GERD Symptoms both after 4 weeks of treatment and after 5 days of treatment. One
RCT found that Esomeprozole more rapidly decreased GERD symptoms compared
to other PPIs but after 5 days showed no difference in efficacy. All trials also found
that 40mg and 20 mg of Esomeprozole showed no significant difference in EE
Healing compared with Omeprozole 20mg.
CONCLUSION: The Results of the three RCTs showed evidence that Esomeprozole
was just as effective as Omeprozole 20mg after 7 days of treatment but had no
difference in efficacy after 4 and 8 weeks of treatment. There was no evidence
found that Esomeprozole had greater efficacy on Esophageal healing at 8 weeks
with 20mg and 40 mgs compared to Ompeprozole 20mg.
KEYWORDS: Omeprozole, Esomeprozole, Erosive Esophagitis, GERD
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Introduction:
GastroEsophageal Reflux Disease or GERD is a very common disease of the
upper GI system that affects about 10-40% of the adult US population. If not treated
this disease can progress into other serious conditions such as erosive esophagitis
(EE), Barrots Esophagus and even Esophageal Cancer. In fact about 40-60% of
patients with GERD will progress to these other serious conditions. Fortunately
these subsequent diseases can be prevented with daily medication such as proton
pump inhibitors with a prescription from your primary care practitioner. Not only
would this medication be beneficial to prevent symptoms and disease progression
but it would also reduce the cost that GERD has on society as a whole. Currently
GERD and its associated diseases is costing American businesses $75 billion per
year in workforce productivity due to the 16 million people scheduling doctors
appointments and diagnostic procedures, keeping people from work; not to mention
the amount Americans spend on treatment and diagnostic studies alone.
GERD results when there is weakening and relaxation of the lower
esophageal sphincter leading to gastric contents to enter the esophagus. As a result
the acidic contents of the stomach causes irritation and erosion of the esophageal
lining. Over time this erosive esophagitis may lead to Barrot’s esophagus in which
the lining of the esophagus goes through histologic changes from squamous cells to
columnar cells. Individuals with barrots are more prone esophageal cancer as a
result of this histologic change. All of these issues could easily be avoided by many
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preventable measures such as measures such as weight loss, change in eating habits,
smoking cessation and elevating the head while sleeping.
Though all of these measures help in reducing GERD symptoms not one of
them measures up to the effectiveness of PPIs such as Esomeprozole (Nexium) or
Omeprozole (Prilosec). PPIs work to reduce the amount of HCL produced by the
parietal cells of the stomach, ultimately reducing the acidity of the stomach and as a
result reducing acid reflux symptoms.
Since PPIs have been developed there have been multiple additions to the
PPI family such as esomeprozole, lansoprozole and Pantoprozole to name a few.
With each new one created there is question of their efficacy when compared to the
others. A prime example is the difference between the safety and efficacy of
Esomeprozole and Omeprozole in treating GERD and GERD related diseases. The
answer to this question is beneficial because Omeprozole is often a cheaper
alternative to Esomeprozole. In order to answer this question a systematic review
was conducted, comparing three RCTs. The SR was done to determine if there is a
difference in safety and efficacy in relieving GERD symptoms and in the healing of
erosive esophagitis.
Objective:
The objective of this systematic review is to determine whether
Esomeprazole (Nexium) is more safe and effective than Omeprazole (Prilosec) in
reducing Heartburn and in increasing the rate of esophageal healing in adults with
GERD and endoscopically diagnosed Erosive Esophagitis (EE).
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Method:
All three trials selected for this systematic review included randomized
controlled trials (RCTs) with adult patients anywhere from 18-85 years old (age
range depending on study) who have been endoscopically diagnosed with Erosive
Esophagitis (EE). Each study included an intervention of Esomeprozole 20-40mg
QD, using Omeprozole 20mg QD as the control group. Some variation did exist
between studies. Although all three trials endoscopically measured the difference
in the healing of EE after 8 weeks and the reduction of GERD symptoms, specifically
heartburn. Two of the studies had treated patients for 8 weeks and one of the
studies for only 7 days. Also, the two 8 week trials measured effects on heartburn
after 4 weeks of treatment and the 7 day study measured the effects on heartburn
every day up until day 5 of treatment. Further specific variations in study are
mentioned below.
In the Lightdale, 2006 study, the experimental group was given
Esomeprozole 20mg QD for 8 weeks and the control group was given omeprozole
20mg QD for 8 weeks. The study measured the patients change in GERD symptoms
at 4 weeks but measured the rate of Esophageal healing at 4 and 8 weeks. The
Schmitt 2006 study was conducted in the exact same format except that
Esomeprozole 40mg was used as the experimental treatment instead of
Esomeprozole 20mg.
The Zheng 2009 study was conducted in a slightly different fashion. The time
frame of this study was 7 days in duration with results recorded using the acid

Mahoney, “Esomeprozole vs. Omeprozole”

6

reflux score; specifics of this scoring system can be found in the “Outcomes
Measured” section. Scores were recorded on days 1 through 5 using Esomeprozole
40mg QD as the experimental group and Omeprozole 20mg as the control group.
Pantoprozole and Lansoprozole were also used in this trial as experimental groups
but these results were disregarded from the review for simplicity sake.
All three article were English speaking and have been written in peer
reviewed journals. Keywords used in the literature search Esomeprozole,
Omeprozole, GERD and Erosive Esophagitis using PubMed and Chochrane
Databases to perform the search. Articles were excluded if not POEMs, RCTs,
written before 2005 and if it did not include symptom based outcomes. Statistics
used in the studied included P values, RRR, ARR NNT and CI.
Outcomes Measured:
Outcomes measured were reduction in GERD symptoms and healing of erosive
esophagitis. Each Article measured symptoms based off of patient daily journals and
symptoms criteria scales. Measurement of esophageal healing was done based off of the
LA Classification in all three the articles. One article measured reduction of GERD
symptoms after 5 days of treatment and the other two measured reduction after 4 weeks
of treatment. Patient participants of the 7 day treatment were assessed based on a 6 point
subjective symptom scale (0: none; 1: mild; 2: mild-moderate; 3: moderate; 4:
moderate-severe; 5: severe and/or intolerable).
Table 1 - Demographics & Characteristics of included studies
Study

Type

#Pt

Age(y

Inclusion

Exclusion

W/

Intervent
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R.N.;20
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274

36-85

Results:

Randomized
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study based
on efficacy
and safety of
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all 4
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criteria
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an
by
endoscopic pylori
serology at
diagnosis
screening; GI
bleeding
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time of the; and
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tested
surgery. H/O of
Zollingernegative
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for H.
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diagnosed
reflux
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tis

motility
disorder,
stricture, or any
serious medical
condition,
including
cancer and
Barrett’s
esophagus.
Same as
Lightdale, C.J.
2006
publication

Active PUD,
upper GI
CA, CA of
other
organs,
cardiac,
hepatic, or
renal
diseases,
anemia,
pregnant
and/or
lactating.

7

D
70

ions
Daily
Administ
ration of
Esomepr
azole
20mg for
4-8
weeks
and Daily
Administ
ration of
Omepraz
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for 4-8
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28
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weeks
and
Omepraz
ole 20mg
QD for 48 weeks
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This Systematic review was done on three randomized controlled trials; two
of which were 8 week comparative trials and one a 7 day trial. All three included
omeprozole 20 mg daily as the control and esomeprozole as the experimental dosed
at either 20mg or 40 mg daily. Patients included in each study were between the
ages of 18-85 and endoscopically diagnosed with Erosive Esophagitis. All
participants were tested for H. Pylori and were only included in the study if test
results came back negative for H. Pylori.
In the Lightdale, 2006 study, after 4 weeks there was found to be no
significant difference in efficacy between the two PPIs in resolving heartburn
(p=0.995); Esomeprozole having 60.6% efficacy and Omeprozole 60.5% efficacy.
Similarly the difference between the two treatments found no statistical significance
in EE healing after 8 weeks (p=0.621); with Esomprozole being 90.6% effective and
Omeprozole being 88.3% effective.
The Schmidt 2006 study, similar data was collected that found no statistical
significance between the experimental and the control group. At 4 weeks,
Esomeprozole 40mg was 65.0% effective and Omeprozole 20mg was 63.1%
effective with a P-value of 0.480. Similarly, At 8 weeks, there was no statistical
significance on the rate of EE healing for either treatments (p=0.552); Esomeprosole
40mg being 92.2% effective and Omeprozole 20mg being 89.8% effective.
The Zheng 2009 study concluded that during the first few days of treatment
some variation existed on GERD symptom reduction showing that Esomeprozole
was of greater efficacy than Omeprozole. By day 5 there was no statistical
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difference in efficacy between the two treatments (p=0.0069). After 8 weeks
patients were brought back in for endoscopic measurement of EE healing.
Endscopic results showed that there was no statistical difference in the rate of
esophageal healing between the two treatments (esomeprozole at 95.4% and
Omeprozole at 87.7%).
Table 2: Esomeprozole vs. Omeprozole on the reduction of GERD symptoms.
Esomeprozole Omeprosole P Value

RBI

ABI

NNT

(EER)

(CER)

Lightdale, 60.6%
2006
(4
weeks)
Schmidt, 65.0%
2006
(4
weeks)
Zheng,
N/A
2009
(5 days)

60.5%

0.995

0.00165 0.001

1000

63.1%

0.48

0.0292

0.019

52.6

N/A

0.0069

N/A

N/A

N/A

Table 3: Esomeprozol vs. Omeprozole in Esophageal healing at 8 weeks of
treatment.
Esomeprozol Omeprosole P Value
(EER)
Lightdale, 90.6%
2006
(8
weeks)
Schmidt,
92.2%

RBI

ABI

NNT

(CER)
88.3%

0.621

0.026

0.023

43.5

89.8%

0.552

0.027

0.024

41.7
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(8
weeks)
Zheng,
2009
(5 days)

95.4%

87.7%

N/A

0.088

0.077
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12.99

To understand why the authors of the article deemed the differences
between each treatment stastistically insignificant the RBI, ABI and NNT were
calculated for each study. This was done by taking the efficacy rates for each
treamtment; Esomeprozole being the Experimental Event Rate (EER) and
omeprozole being the Controled Event Rate (CER). Both were used to calculate the
Relative Benefit Increased (RBI) and the Absolute Benefit Increase (ABI). The ABI
was then used to calculate Numbers Needed to Treat (NNT). Numbers needed to
treat will tell us how many patents need to be treated in order to have
Esomeprozole show some statistical significance in efficacy over Omeprozole.
In Lightdales study, in order for Esomeprozole to have show significant
benefit over Omeprozole for treating heartburn about 1000 people would need to
be treated and about 43.5 people would need to be treated to show a benefit for EE
healing. In the Schmidt 2006 study, 52.6 patients would need to be treated to show
a greater benefit in heartburn treatment and 41.7 for EE healing. The Zheng 2009
study, it wasn’t possible to calculate NNT for Heartburn treatment but it did show
that Esomeprozole was slightly more beneficial than Omeprozole with an NNT of
12.99.
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Safety: Only the Lightdale 2006 and Schmidt 2006 studies documented
Adverse Effects of their treatments. Both studies showed similar results in safety
between the experimental and control. Four of the most common side effects of
both drugs were HA, Gastritis, Diarrhea and Respiratory infection. In both studies,
Esomeprozole and Omeprozole yielded similar percentages in Adverse Effects(AE)
with Esomeprozole having slightly higher incidences of AE in all types. Specific
numbers and percentages can be found in tables 4 and 5. Despite a few Adverse
side effects reported by some patients overall the two drugs were very well
tolerated during the study.
Table 4: Common Adverse Effects of Esomeprozole and Omeprozole from
Lightdale 2006.
Headaches

Gastritis

Diarrhea

Resp.
Infection

Esomeprozole 58 (9.9%)

31 (5.3%)

27 (4.6%)

27 (4.6%)

Omeprozole

18 (3.1%)

28 (4.8%)

25 (4.3%)

37 (6.3%)

Table 5: Common Adverse Effects of Esomeprozole and Omeprozole from
Schmidt 2006 Study
Headaches

Gastritis

Diarrhea

Resp.
Infection

Esomeprozole 59 (10.2%)

28 (4.9%)

38 (6.6%)

26 (4.5%)
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39 (6.8%)

18 (3.2%)

31 (5.4%)

12

16 (2.8%)

Discussion:
Historically PPIs are very safe and effective drugs used to treat GERD and
other gastric diseases such as ulcers and H. Pylori infections. These studies have
indicated that PPIs are also effective in treating Erosive Esophagitis. EE is a disease
that is often a result of chronic GERD and heartburn. As a result of these
observations, it can be hypothesized that aggressive treatment of GERD with PPI
therapy ultimately reduces the damaging affects of GERD on the esophagus and
allows for prevention and quicker healing of erosive esophagitis.
Other similar studies may be performed to test this hypothesis and to
provide more concrete evidence that PPI therapy is a safe and effective treatment
for erosive esophagitis. If enough evidence is collected, it will be easier to educate
patients on the effectiveness of PPI therapy an adequate preventative treatment of
erosive esophagitis and other diseases caused by GERD. This type of preventive
measure would not only reduce the uncomfortable and dangerous problems
individual patients have with Esophageal disease. It can also reduce the amount of
money American spends each year on GERD and related diseases.
Conclusion:
After reviewing all three articles and comparing the results, it has been
concluded that there is no overall, statistically significant difference between
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Esomeprozole and Omeprozole for the treatment of GERD symptoms or for EE
Healing. From the Zheng 2009 study results, it is possible that Esomeprozole might
provide reduction GERD symtoms quicker than Omeprozole in the first 1-2 days of
treatment; but by the 5th day of treatment, Omeprozole was fount to be just as
effective as Esomeprozole in symptom reduction. In light of these findings, it would
be beneficial to perform more 7 day trials of PPI treatment to determine if these
findings are credible and to determine if Esomeprozole would be a better choice if
one was looking for the quickest way to successfully reduce GERD symptoms.
It was mentioned in Lighdale 2006 study that when comparing the healing
rate of 4 and 8 weeks, the rate of esophageal healing although, not significant at 8
weeks, was beginning to approach significance. This opens up the possibility that, if
given for a longer duration, Esomeprozole could show a significant difference in
efficacy with regards to esophageal healing rates compared to Omeprozole. It would
be beneficial to "attempt this experiment again for a longer period of time; for about
12 to 16 weeks.
After reviewing the methods section of each article it was noted that certain
variable that were not controlled for and may be beneficial in future studies to more
definitively confirm the similar efficacy of these two medications. One specific
variable is the dietary habits of the participants. There was no mention of control in
the patients dietary habits. This could have had an impact on GERD symptom
presentation and exacerbations of participants. In order to control for this it would
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be beneficial to put all participants on a diet restricting individuals from foods
known to exacerbate GERD symptoms.
In conclusion It has been determined by this systematic review that both
Esomeprozole and Omeprozole are equally safe and effective in treating GERD
symptoms and for improving the rate of EE healing. If patients propose that the
cannot afford the more expensive esomeprozole then the physician can offer the
alternative of the cheaper Omeprozole to the patient. The Physician should explain
to the patient that Omeprozole may not be as effective in the first few days but if
given time is just as safe and effective as its more expensive counterpart.
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